Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Long-term Iron Absorption and Loss in Women

28. září 2026 aktualizováno: Tippawan Pongcharoen, Mahidol University

Long-term Iron Absorption and Loss in Overweight/Obese Thai Middle-aged Women

Obese people typically have chronic low-grade inflammation. Based on short-term studies, this inflammation could affect the absorption, utilization, storage, and mobilization of iron, and individuals with inflammation might develop iron deficiency (ID) and anemia when inadequacy of iron intake is presented. The double burden of malnutrition is nowadays emerging as a major public health concern in many countries, including Thailand. Understanding the association of chronic inflammation among people with overweight or obesity (OW/OB) with long-term iron absorption and loss is important for developing appropriate policies and programs to promote iron balance and, consequently, optimal iron status and health outcomes. Since previous reports among Thai women showed a high prevalence of OW/OB and anemia, this study will be conducted to determine the long-term iron absorption and loss among OW/OB free-living women using the iron isotope dilution method.

Přehled studie

Detailní popis

  1. Research Objective To study iron absorption, loss, and long-term iron gain in overweight or obese middle-aged Thai women compared with normal-weight middle-aged Thai women.
  2. Research Methodology 2.1 Study design: This study is a longitudinal study comparing long-term iron absorption and loss between overweight or obese middle-aged Thai women and normal-weight middle-aged Thai women.

2.2 Study population: The study population consists of 64 women aged 40-50 years, divided into two groups: 32 overweight or obese women, and 32 normal-weight women.

2.3 Research Procedures 2.3.1 Before data collection: The research protocol is submitted for approval to the Central Institutional Review Board, Mahidol University. All data collectors will be trained prior to fieldwork. Upon receiving ethical approval, recruitment posters will be used to invite participants.

Screening process:

  1. Interested individuals meeting preliminary eligibility criteria will be informed about study details, sign informed consent, and schedule the first visit for screening and blood collection.

  2. Visit 1 (Screening):

    • Collect demographic and health history, measure weight, height, and body composition.
    • Collect 5 mL blood sample for Hb, SF, CRP, AGP, and hemoglobin typing.
    • Perform urine pregnancy test.
    • Administer one 400 mg albendazole tablet to prevent parasitic infection.

Iron isotope administration and follow-up:

2.3.2 Eligible participants will return within 1-2 weeks for the second visit.

Visit 2 (Month 0; M0):

Participants will consume a 15 mg ⁵⁷Fe isotope solution followed by 100 mg vitamin C drink, then fast for 3 hours.

A snack (plain yogurt and water) will be provided 1.5 hours after ingestion. A 24-hour dietary recall and semi-quantitative food frequency questionnaire (FFQ) will be conducted, with two additional 24-hour recalls by phone (2 weekdays and 1 weekend day).

Participants will then enter a 1-year equilibration period, recording illness and menstrual data monthly. The research team will monitor via LINE or email.

Visit 3 (Month 9; M9):

Collect fasting blood (5 mL) for Hb, glucose, HbA1c, and lipid profile; measure weight, BP, and conduct 24-hour recall (plus two by phone).

Visit 4 (After 1 year; WK0):

Collect fasting blood (10 mL) for Hb, SF, TfR, CRP, AGP, erythrocyte isotopic enrichment.

Measure weight, body composition, pregnancy test, and dietary recalls (3 days) and FFQ.

Visits 5-7 (WK8, WK16, WK24):

For eligible participants, repeat blood tests (7 mL) for Hb, SF, TfR, CRP, AGP, isotopic enrichment, anthropometry, pregnancy test, 3-day dietary recalls, and FFQ.

2.4 Research Instruments

  1. General information and medical history questionnaire, 24-hour dietary recall, and FFQ.

  2. Illness and menstrual record forms.

  3. Anthropometry and clinical measures:

    • Weight: InBody digital scale
    • Height: Harpenden stadiometer
    • Body composition: Bioelectrical Impedance Analyzer (BIA; InBody)
    • Blood pressure: Omron digital sphygmomanometer
  4. Laboratory analyses:

    • Hb: Complete Blood Count (CBC) using flow cytometry
    • SF, TfR, CRP, AGP: ELISA (SFa calculated from SF, CRP, AGP)
    • Hemoglobin typing: Capillary electrophoresis
    • Fasting glucose: Enzymatic method
    • HbA1c: Turbidimetric inhibition immunoassay
    • Lipids: Enzymatic colorimetric and homogeneous methods
    • Iron isotopes: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 2.5 Data Analysis Nutrient intake (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated using INMUCAL software.

Dietary patterns will be analyzed using Principal Component Analysis (PCA).

The average iron absorption (Fe_abs) over the study period will be calculated as:

Feabs=kabs×FetotalFe_{abs} = k_{abs} \times Fe_{total}Feabs=kabs×Fetotal where Fe_total is the total body iron at the midpoint estimated from the regression of Fe_total over time, and k_abs is the fractional iron absorption rate derived from the slope of the regression line of ln(⁵⁷Fe) vs. time.

Average iron loss (Fe_loss) is calculated similarly:

Feloss=kloss×FetotalFe_{loss} = k_{loss} \times Fe_{total}Feloss=kloss×Fetotal

Iron gain (Fe_gain) is calculated as:

Fegain=Feabs-FelossFe_{gain} = Fe_{abs} - Fe_{loss}Fegain=Feabs-Feloss Differences between groups in general characteristics, biochemical parameters, and iron absorption/loss slopes will be tested using Independent t-test or Mann-Whitney U-test, as appropriate.

A Linear Mixed-Effects Model will be used to analyze group differences in longitudinal changes of iron absorption, loss, and gain.

Statistical significance will be set at p < 0.05.

Typ studie

Pozorovací

Zápis (Odhadovaný)

64

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

  • Jméno: Aree Prachansuwan, Ph.D.
  • Telefonní číslo: +66890060602

Studijní místa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

40 let až 50 let (Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Ženský

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

The study population will consist of 64 women aged 40-50 years, divided into two groups: 32 participants who are overweight or obese, and 32 participants with normal weight.

Popis

Inclusion Criteria:

  • Normal weight group

    1. Aged 40-50 years
    2. Normal weight (BMI 18.5-22.9 kg/m²)
    3. Hb ≥12.0 g/dL and inflammation-adjusted SFa <50.0 µg/L
    4. CRP <5.0 mg/L
    5. Normal hemoglobin typing
    6. Plans to reside in the study area for >2 years
  • Overweight/obese group

    1. Aged 40-50 years
    2. Overweight or obese [Body Mass Index (BMI) ≥25.0 kg/m²] - the BMI cut-off follows the agreement of countries under the Coordinated Research Project (CRP) E43038 "Using the iron isotope dilution technique to assess the influence of inflammation on long-term iron absorption and loss," supported by the IAEA
    3. Hemoglobin (Hb) ≥12.0 g/dL and inflammation-adjusted serum ferritin (SFa) <50.0 µg/L
    4. C-reactive protein (CRP) between 5.0-25.0 mg/L
    5. Normal hemoglobin typing
    6. Plans to reside in the study area for >2 years

Exclusion Criteria:

  • Normal weight group

    1. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
    2. Having metabolic NCDs (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
    3. Pregnant, breastfeeding, or planning pregnancy during the study
    4. Chronic infectious disease (e.g., tuberculosis, AIDS)
    5. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
    6. Taking vitamin or mineral supplements during or within two weeks prior to the study
    7. Participating in a weight-loss program
    8. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
    9. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
    10. Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)
  • Overweight/obese group

    1. Obesity class II (BMI ≥35.0 kg/m²) with high health risk
    2. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
    3. Having metabolic noncommunicable diseases (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
    4. Pregnant, breastfeeding, or planning pregnancy during the study
    5. Chronic infectious disease (e.g., tuberculosis, AIDS)
    6. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
    7. Taking vitamin or mineral supplements during or within two weeks prior to the study
    8. Participating in a weight-loss program
    9. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
    10. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
    11. Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: PROSPECTIVE

Kohorty a intervence

Skupina / kohorta
Normal weight

BMI 18.5-22.9 kg/m2

Overweight or obesity

BMI 25-35 kg/m2

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Mean long-term iron absorption (Fe abs)
Časové okno: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).

Calculated over the duration of the study as follows: Fe abs = k abs x Fe total Where Fe total is the total body iron at the midpoint, calculated from the linear regression of Fe total versus time across each measurement point; and k abs is the fraction of total body iron absorbed per unit of time (derived from the slope of the linear regression equation of ln 57 Fe versus time).

57 Fe isotope will be measured using Inductively Coupled Plasma Mass Spectrometry (ICP-MS).

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).
Mean long-term iron loss (Fe loss)
Časové okno: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Calculated in the same manner as iron absorption: Fe loss = k loss x Fe total Where k loss is the fraction of total body iron lost per unit of time.

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Iron gain (Fe gain)
Časové okno: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Calculated as net iron balance: Fe gain = Fe abs - Fe loss

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Weight (kg)
Časové okno: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Weight will be measured in kg (to the nearest 0.1 kg) using an Inbody digital weighing scale.

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Height (cm)
Časové okno: Visit 1 (Screening)

Height will be measured to the mearest 0.1 cm using a Harpenden stadiometer.

Visit 1 (Screening)
Body Mass Index (BMI, kg/m²)
Časové okno: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

BMI will be calculatedn body weight in kilograms divided by height in meters squared.

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Body composition (fat mass)
Časové okno: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)

Body composition (fat mass) will be measured using the Bioelectrical Impedance Analyzer (BIA; InBody).

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
Nutrient intakes
Časové okno: Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Nutrient intakes (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated from 3-day 24-hr dietary recalls using INMUCAL software.

Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Dietary pattern
Časové okno: Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)

Dietary patern from FFQ will be analyzed using the Principal Component Analysis (PCA)

Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
Hemoglobin (Hb, g/L)
Časové okno: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Hb concentration will be assessed using flow cytometry

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Serum ferritin (SF, µg/L)
Časové okno: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

SF will be measured using Enzyme-linked immunosorbent assay (ELISA)

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
serum transferrin receptor (sTfR µg/L)
Časové okno: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

sTfR will be assessed using ELISA

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
c-reactive protein (CRP, mg/L)
Časové okno: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

CRP will measured using ELISA

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
alpha-1 acid glycoprotein (AGP, g/L)
Časové okno: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

AGP will be measured using ELISA

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Glycated hemoglobin (HbA1c, %)
Časové okno: Visit 3 (Month 9)

HbA1c wil be measured by Turbidimetric inhibition immunoassay

Visit 3 (Month 9)
Lipid profile
Časové okno: Visit 3 (Month 9)

Lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) will be measured using Enzymatic colorimetric and homogeneous methods.

Visit 3 (Month 9)
Blood pressure (BP, mmHg)
Časové okno: Visit 3 (Month 9)

BP will be measured using Omron digital sphygmomanometer

Visit 3 (Month 9)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Ředitel studie: Veronica LOPEZ TEROS, Ph.D., Internation Atomic Energy Agency

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

8. května 2025

Primární dokončení (Odhadovaný)

31. prosince 2027

Dokončení studie (Odhadovaný)

31. srpna 2028

Termíny zápisu do studia

První předloženo

6. srpna 2026

První předloženo, které splnilo kritéria kontroly kvality

28. září 2026

První zveřejněno (Aktuální)

2. října 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

2. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

28. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Popis plánu IPD

There has been ongoing discussion regarding collaboration on data analysis and publication among countries that have conducted studies supported by the International Atomic Energy Agency (IAEA).

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit